Catalyst Pharmaceuticals

Yahoo Finance • 4 days ago

Notable healthcare headlines for the week: UnitedHealth, Pfizer, and CVS Health in focus

Wall Street’s major market averages ended higher on Friday as investors digested the latest nonfarm payrolls print and sidestepped the ongoing tensions in the Middle East. The blue-chip Dow added +0.1%, the benchmark S&P 500 closed +0.8%,... Full story

Yahoo Finance • 5 days ago

This Biotech Stock Has Soared 175%. Here’s Why One Fund Still Sold $3 Million Worth

On May 8, 2026, JW Asset Management reported selling 83,600 shares of Liquidia Corporation(NASDAQ:LQDA), an estimated $3.10 million trade based on quarterly average pricing. What happened According to an SEC filing dated May 8, 2026, JW... Full story

Yahoo Finance • 8 days ago

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration of approximately 4.1 billion USD, repre... Full story

Yahoo Finance • 17 days ago

Sector Update: Health Care Stocks Softer in Afternoon Trading

Health care stocks were lower Monday afternoon with the NYSE Health Care Index easing 0.1% and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference

CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for... Full story

Yahoo Finance • 3 months ago

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% FIRDAPSE® (amifampridine) Growth and 67.... Full story

Yahoo Finance • 4 months ago

Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move?

Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals(NASDAQ:CPRX), exercised and immediately sold 10,983 shares of common stock on November 26, 2025, for a total value of approximately $256,200, as disclosed in this SEC... Full story

Yahoo Finance • 5 months ago

Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • 5 months ago

Analysts See Big Upside in Catalyst Pharmaceuticals, Inc. (CPRX)

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a consensus Buy with all seven analysts covering it assigning it... Full story

Yahoo Finance • 6 months ago

Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • 6 months ago

Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™

CORAL GABLES, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • 6 months ago

Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference

CORAL GABLES, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • 6 months ago

Catalyst raises 2025 revenue guidance to $565M–$585M while launching $200M share buyback program

Earnings Call Insights: Catalyst Pharmaceuticals (CPRX) Q3 2025 MANAGEMENT VIEW * Richard John Daly, President and CEO, stated that "Catalyst delivered outstanding third quarter 2025 results with accelerating momentum, strong demand fo... Full story

Yahoo Finance • 6 months ago

Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Reported Q3 2025 Total Revenues of $148.4Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance to between $565 Million and $585 Mi... Full story

Yahoo Finance • 6 months ago

Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work

CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • 6 months ago

Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference

CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • 7 months ago

Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025

CORAL GABLES, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • 7 months ago

Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences

CORAL GABLES, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for pe... Full story

Yahoo Finance • 7 months ago

Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program

CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel med... Full story

Yahoo Finance • 8 months ago

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Value Investing Opportunity with Strong Fundamentals

The practice of value investing centers on identifying companies trading below their intrinsic worth, a strategy pioneered by Benjamin Graham and later refined by investors like Warren Buffett. This approach emphasizes purchasing securitie... Full story